1.王丽.儿科药理学与药物治疗学.北京:北京医科大学出版社，2002:31-54

2.魏敏吉，赵明.创新药物药代动力学研究与评价.北京:北京大学医学出版社，2008:3-66

3.魏树礼，张强.生物药剂学与药物动力学.第2版.北京:北京大学医学出版社，2004:90-189

4.Rosenbaum SE.Basic Pharmacokinetics and Pharmacodynamics-an integrated textbook and computer simulations.Singapore:John Wiley＆Sons，Inc.，2011:126-200

5.国家食品药品监督管理局.化学药物非临床药代动力学研究技术指导原则.2005

6.国家食品药品监督管理局.化学药物临床药代动力学研究技术指导原则.2005

7.FDA.General considerations for pediatric pharmacokinetic studies for drugs and biological products.1998

8.FDA.Pharmacokinetics in Patients with Impaired Renal Function-Study Design，Data Analysis，and Impact on Dosing and Labeling.2010

9.FDA.Pharmacokinetics in Patients with Impaired Hepatic Function:Study Design，Data Analysis，and Impact on Dosing and Labeling.2003

10.FDA.Population Pharmacokinetics.1999

11.FDA.Exposure-Response Relationships-Study Design，Data Analysis，and Regulatory Applications.2003

12.Derendorf H，Meibohm B.Modeling of pharmacokinetic/pharmacodynamic(PK-PD)relationships:concepts and perspectives.Pharm Res，1999，16(2):176-185

13.Derendorf H，Lesko LJ，Chaikin P，et al.Pharmacokinetic/pharmacodynamic modeling in drug research and development.J Clin Pharmacol，2000，40(12 pt 2):1399-1418

14.Meibohm B，Derendorf H.Basic concepts of pharmacokinetic/pharmacodynamic(PK-PD)modelling.Int J Clin Pharmacol Ther，1997，35(10):401-413

15.Levy G.Kinetics of pharmacologic effects.Clin Pharmacol Ther，1996，7:362

16.Wagner JG.Kinetics of pharmacologic response;Ⅰ.Proposed relationships between response and drug concentration in the intact animal and man.J Theor Biol，1968，20(2):173

17.Sheiner LB，Stanski DR，Vozeh S，et al.Simultaneous modeling of pharmacokinetics and pharmaco-dynamics:Application to d-tubocurarine.Clin Pharmacol Ther，1979，51(3):235

18.John J.Lima，Matsushima NKissoon N，Wang J，et al.Modeling the metabolic effects of terbutaline in β ₂-adrenergic receptor diplotypes.Clin Pharmacol Ther，2004，2004，76(1):27